Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache.
CompletedPhase 4NCT00212810
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study is to determine whether Topiramate is effective in preventing the development of chronic daily headache among patients with episodic migraine headaches.
Study details
- Official title
- TOPAMAX (Topiramate) Intervention to Prevent Transformation of Episodic Migraine: The Topiramate INTREPID Study
- Interventions
- Sponsor
- Ortho-McNeil Neurologics, Inc.
- Start date
- 2005-09
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * To qualify for this study you must be 18-65 years old * have a history of migraine headaches for at least 1 year * experience at least 10 but less than 15 migraine headache days and less than 15 total headache days/month * able to take oral medication * able to understand and sign the informed consent and to complete headache diaries. Exclusion Criteria: * You will not be able to participate in the study if you previously discontinued Topiramate because it did not make you feel better or it made you feel different * have migraine aura without headache * have a positive urine drug screen * have a history of kidney stones * have a history of suicide attempt * pregnant females * already on a migraine preventive medicine.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00212810